229 related articles for article (PubMed ID: 7526367)
1. Adverse perinatal outcome in patients screen-positive for neural tube defects and fetal Down syndrome.
Gross SJ; Phillips OP; Shulman LP; Bright NL; Dungan JS; Simpson JL; Elias S
Prenat Diagn; 1994 Jul; 14(7):609-13. PubMed ID: 7526367
[TBL] [Abstract][Full Text] [Related]
2. 'Dual positivity' for neural tube defects and down syndrome at maternal serum screening: gestational outcome.
Zanini R; Tarantini M; Cerri V; Jacobello C; Bellotti D; Lancetti S; Scalchi S; Groli C; Bianchi UA
Fetal Diagn Ther; 1998; 13(2):106-10. PubMed ID: 9650657
[TBL] [Abstract][Full Text] [Related]
3. Obstetrical complications associated with abnormal maternal serum markers analytes.
Gagnon A; Wilson RD;
J Obstet Gynaecol Can; 2008 Oct; 30(10):918-932. PubMed ID: 19038077
[TBL] [Abstract][Full Text] [Related]
4. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
[TBL] [Abstract][Full Text] [Related]
5. Maternal serum triple analyte screening and adverse pregnancy outcome.
Milunsky A; Nebiolo L
Fetal Diagn Ther; 1996; 11(4):249-53. PubMed ID: 8823604
[TBL] [Abstract][Full Text] [Related]
6. Adverse pregnancy outcome after a false-positive screen for Down syndrome using multiple markers.
Pergament E; Stein AK; Fiddler M; Cho NH; Kupferminc MJ
Obstet Gynecol; 1995 Aug; 86(2):255-8. PubMed ID: 7542379
[TBL] [Abstract][Full Text] [Related]
7. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study.
Phillips OP; Elias S; Shulman LP; Andersen RN; Morgan CD; Simpson JL
Obstet Gynecol; 1992 Sep; 80(3 Pt 1):353-8. PubMed ID: 1379701
[TBL] [Abstract][Full Text] [Related]
8. Increased maternal serum alpha-fetoprotein and human chorionic gonadotropin in compromised pregnancies other than for neural tube defects or Down syndrome.
Beekhuis JR; Van Lith JM; De Wolf BT; Mantingh A
Prenat Diagn; 1992 Aug; 12(8):643-7. PubMed ID: 1279656
[TBL] [Abstract][Full Text] [Related]
9. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol.
Cheng EY; Luthy DA; Zebelman AM; Williams MA; Lieppman RE; Hickok DE
Obstet Gynecol; 1993 Jan; 81(1):72-7. PubMed ID: 7677967
[TBL] [Abstract][Full Text] [Related]
10. Second trimester total human chorionic gonadotropin, alpha-fetoprotein and unconjugated estriol in predicting pregnancy complications other than fetal aneuploidy.
Duric K; Skrablin S; Lesin J; Kalafatic D; Kuvacic I; Suchanek E
Eur J Obstet Gynecol Reprod Biol; 2003 Sep; 110(1):12-5. PubMed ID: 12932863
[TBL] [Abstract][Full Text] [Related]
11. Prenatal screening for Down's syndrome with use of maternal serum markers.
Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB
N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344
[TBL] [Abstract][Full Text] [Related]
12. Choroid plexus cysts: Is biochemical testing a valuable adjunct to targeted ultrasonography?
Sullivan A; Giudice T; Vavelidis F; Thiagarajah S
Am J Obstet Gynecol; 1999 Aug; 181(2):260-5. PubMed ID: 10454666
[TBL] [Abstract][Full Text] [Related]
13. [Predictive value of abnormal second-trimester maternal serum triple screening markers for adverse pregnancy outcomes].
Hu Z; Liu X; Li L; Jia C; Li D; Liu R
Zhonghua Fu Chan Ke Za Zhi; 2014 Oct; 49(10):749-53. PubMed ID: 25537246
[TBL] [Abstract][Full Text] [Related]
14. Maternal serum screening.
Carroll JC
Can Fam Physician; 1994 Oct; 40():1756-64. PubMed ID: 7524838
[TBL] [Abstract][Full Text] [Related]
15. Triple marker (alpha-fetoprotein, unconjugated estriol, human chorionic gonadotropin) versus alpha-fetoprotein plus free-beta subunit in second-trimester maternal serum screening for fetal Down syndrome: a prospective comparison study.
Kellner LH; Weiner Z; Weiss RR; Neuer M; Martin GM; Mueenuddin M; Bombard A
Am J Obstet Gynecol; 1995 Oct; 173(4):1306-9. PubMed ID: 7485343
[TBL] [Abstract][Full Text] [Related]
16. Unexplained elevated midtrimester maternal serum levels of alpha fetoprotein, human chorionic gonadotropin, or low unconjugated estriol: recurrence risk and association with adverse perinatal outcome.
Wax JR; Lopes AM; Benn PA; Lerer T; Steinfeld JD; Ingardia CJ
J Matern Fetal Med; 2000; 9(3):161-4. PubMed ID: 10914623
[TBL] [Abstract][Full Text] [Related]
17. Prediction of adverse perinatal outcome by maternal serum screening for Down syndrome in an Asian population.
Hsieh TT; Hung TH; Hsu JJ; Shau WY; Su CW; Hsieh FJ
Obstet Gynecol; 1997 Jun; 89(6):937-40. PubMed ID: 9170469
[TBL] [Abstract][Full Text] [Related]
18. Elevated maternal urine level of beta-core fragment of human chorionic gonadotropin versus serum triple test in the second-trimester detection of down syndrome.
Bahado-Singh R; Oz U; Rinne K; Hunter D; Cole L; Mahoney MJ; Baumgarten A
Am J Obstet Gynecol; 1999 Oct; 181(4):929-33. PubMed ID: 10521756
[TBL] [Abstract][Full Text] [Related]
19. Risk of abnormal triple screen for Down syndrome is significantly higher in patients with female fetuses.
Spong CY; Ghidini A; Stanley-Christian H; Meck JM; Seydel FD; Pezzullo JC
Prenat Diagn; 1999 Apr; 19(4):337-9. PubMed ID: 10327139
[TBL] [Abstract][Full Text] [Related]
20. Maternal serum alpha-fetoprotein and fetal triploidy.
Pircon RA; Towers CV; Porto M; Gocke SE; Garite TJ
Prenat Diagn; 1989 Oct; 9(10):701-7. PubMed ID: 2480590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
